Skip to main content
Clinical Trials/NCT07293884
NCT07293884
Not yet recruiting
Not Applicable

Efficacy of Nebulized Versus Intravenous N- Acetylcysteine in Airway Clearance in Broncheictasis

Assiut University0 sites70 target enrollmentStarted: December 1, 2025Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
70
Primary Endpoint
sputum viscosity score

Overview

Brief Summary

It has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to enhance the therapeutic efficacy for bronchiectasis . Mucoactive drugs are commonly used to clear the airway in mucus hypersecretion diseases. Currently, investigators have found that N-acetylcysteine (NAC), an effective mucolytic agent, not only reduces the viscosity and elasticity of sputum, but it also has anti-inflammatory and antioxidant activity.

Additionally, the Spanish guidelines on the treatment of bronchiectasis indicate that the use of N-acetylcysteine should be considered for patients with bronchiectasis and COPD. Therefore, as a classic mucolytic agent with antioxidant and anti-inflammatory properties, N-acetylcysteine can be effective in the treatment of bronchiectasis

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subjects aged above 18 years old; with a diagnosis of bronchiectasis who are admitted to chest department due to acute exacerbation

Exclusion Criteria

  • current smokers, a known allergy to N-acetylcysteine; pregnancy or lactation (for women); primary diagnosis of COPD or asthma

Arms & Interventions

IV N Acetyle cysteine

Active Comparator

Intervention: N Acetyle cysteine given by IV injection

Intervention: N Acetyle cysteine given by IV injection (Drug)

Nebulized N Acetyle cysteine

Active Comparator

Intervention: Nebulized N Acetyle cysteine

Intervention: Nebulized N Acetyle cysteine (Drug)

Outcomes

Primary Outcomes

sputum viscosity score

Time Frame: At the end of 1 week of treatment

Sputum viscosity score \\(0\\): Normal (liquid)\\(1\\): Mildly increased viscosity (fluid)\\(2\\): Moderately increased viscosity (viscous)\\(3\\): Severely increased viscosity (sticky)

Amount of sputum

Time Frame: At the end of 1 week treatment

Expectoration difficulty score

Time Frame: At the end of 1 week of treatment

Expectoration difficulty score \\(0\\): No difficulty\\(1\\): Mild difficulty\\(2\\): Moderate difficulty\\(3\\): Marked difficulty

Secondary Outcomes

  • Need for mechanical ventilation(At the end of 1 week of treatment)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Sahar Refaat Mahmoud

Dr

Assiut University

Similar Trials